We are live on ! Find out more
ADCT icon

ADC Therapeutics
ADCT

58 hedge funds and large institutions have $273M invested in ADC Therapeutics in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 9 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 4

69% more call options, than puts

Call options by funds: $198K | Put options by funds: $117K

67% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 9

18% more funds holding

Funds holding: 49 → 58 (+9)

0.46% more ownership

Funds ownership: 44.43% → 44.88% (+0.46%)

46% less capital invested

Capital invested by funds: $501M → $273M (-$229M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
58
Holders Change
+9
Holders Change %
+18.37%
% of All Funds
0.98%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
15
Increased
15
Reduced
9
Closed
4
Calls
$198K
Puts
$117K
Net Calls
+$81K
Net Calls Change
-$256K

Top Buyers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
+$6.06M
2
BlackRock
BlackRock
New York
+$1.54M
3
ECM
ExodusPoint Capital Management
New York
+$1.32M
4
Morgan Stanley
Morgan Stanley
New York
+$1.13M
5
Principal Financial Group
Principal Financial Group
Iowa
+$954K

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$4.74M
2
VCG
Vantage Consulting Group
Virginia
-$4.67M
3
EAM
Eventide Asset Management
Massachusetts
-$899K
4
AA
ALPS Advisors
Colorado
-$315K
5
VEA
Virtus ETF Advisers
New York
-$282K
Name Holding Trade Value Shares
Change 		Change in
Stake
Allianz Asset Management
26
Allianz Asset Management
Germany
$491K -$57.2K -6,050 -9%
ECM
27
Endurant Capital Management
California
$469K +$558K +58,967 New
Millennium Management
28
Millennium Management
New York
$461K +$548K +57,965 New
AA
29
ALPS Advisors
Colorado
$362K -$315K -33,282 -42%
HWAM
30
Hennion & Walsh Asset Management
New Jersey
$308K +$366K +38,700 New
WP
31
Woodline Partners
California
$269K +$320K +33,841 New
Rockefeller Capital Management
32
Rockefeller Capital Management
New York
$198K +$842 +89 +0.4%
Zurich Cantonal Bank
33
Zurich Cantonal Bank
Switzerland
$170K – – –
MGIA
34
Moneta Group Investment Advisors
Missouri
$155K +$265 +28 +0.1%
Lazard Asset Management
35
Lazard Asset Management
New York
$127K +$152K +16,098 New
CF
36
CNA Financial
Illinois
$123K – – –
State Street
37
State Street
Massachusetts
$112K +$133K +14,028 New
GCM
38
Graham Capital Management
Connecticut
$103K +$123K +12,992 New
Squarepoint
39
Squarepoint
New York
$88K +$104K +11,014 New
CCG
40
Cypress Capital Group
Florida
$80K +$94.6K +10,000 New
Bank of America
41
Bank of America
North Carolina
$50K -$12K -1,267 -17%
Osaic Holdings
42
Osaic Holdings
Arizona
$44K +$21.1K +2,235 +69%
QT
43
Quantbot Technologies
New York
$38K +$45.9K +4,852 New
Royal Bank of Canada
44
Royal Bank of Canada
Ontario, Canada
$12K +$5.68K +600 +67%
SIAP
45
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$9K – – –
BCV
46
Banque Cantonale Vaudoise
Switzerland
$8K – – –
TRCT
47
Tower Research Capital (TRC)
New York
$6K -$350 -37 -5%
AssetMark Inc
48
AssetMark Inc
California
$3K +$1.89K +200 +121%
US Bancorp
49
US Bancorp
Minnesota
$2K -$473 -50 -14%
FWM
50
Focused Wealth Management
New York
$2K – – –
1
2
3

ADCT Hedge Fund Activity: Q2 2022 in Review

58 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q2 2022, worth a combined $273M — down 46% from $501M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ADCT positions and 4 closed out — a net gain of 11 holders — while 15 added to existing stakes and 9 trimmed.

The largest buyer was Walleye Capital, adding an estimated $6.06M. The largest seller was T. Rowe Price Associates, cutting an estimated $4.74M.

  • 58 institutional investors held ADC Therapeutics (ADCT) as of Q2 2022, up from 49 in Q1 2022.
  • Funds reported $273M of ADC Therapeutics stock for Q2 2022, down 46% quarter-over-quarter.
  • 15 funds opened new ADC Therapeutics positions in Q2 2022 and 4 closed out, a net change of +11 holders.
  • The largest ADC Therapeutics buyer in Q2 2022 was Walleye Capital, an estimated $6.06M added.
  • The largest ADC Therapeutics seller in Q2 2022 was T. Rowe Price Associates, an estimated $4.74M sold.

Based on aggregated 13F filings for Q2 2022.